Literature DB >> 26052050

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Giandomenico Roviello1, Roberto Petrioli2, Letizia Laera2, Edoardo Francini3.   

Abstract

New agents for metastatic castration-resistant prostate cancer (CRPC) developed in the past 3 years include cabaziataxel (Cbz), abiraterone acetate (AA) and enzalutamide (E). In this review, the results of clinical studies in which one of these drugs is included as the third line of treatment are discussed. Our review suggests that AA and E have limited activity, while Cbz seems to retain its efficacy. Prospective studies that further examine sequential treatments are warranted.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Abiraterone acetate; Cabazitaxel; Enzalutamide; Prostate cancer; Sequential therapy

Mesh：

Substances：

Year:  2015        PMID： 26052050     DOI： 10.1016/j.critrevonc.2015.04.010

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  7 in total

1.  How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancer.

Authors:  Giandomenico Roviello; Benedetta Panella
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-22

2.  Is there still a place for docetaxel rechallenge in prostate cancer?

Authors:  Roberto Petrioli; Edoardo Francini; Giandomenico Roviello
Journal:  World J Clin Oncol       Date:  2015-10-10

3.  Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis.

Authors:  Giandomenico Roviello; Daniele Generali
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

Review 4.  Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.

Authors:  Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.

Authors:  Vinay Sagar; Rajita Vatapalli; Barbara Lysy; Sahithi Pamarthy; Jonathan F Anker; Yara Rodriguez; Huiying Han; Kenji Unno; Walter M Stadler; William J Catalona; Maha Hussain; Parkash S Gill; Sarki A Abdulkadir
Journal:  Cell Death Dis       Date:  2019-10-22       Impact factor: 8.469

6.  A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Lawrence Fong; Michael J Morris; Andrew J Armstrong; Daniel P Petrylak; Oliver Sartor; Celestia S Higano; Lance Pagliaro; Ajjai Alva; Leonard J Appleman; Winston Tan; Ulka Vaishampayan; Raphaelle Porcu; Darren Tayama; Edward E Kadel; Kobe C Yuen; Asim Datye
Journal:  Clin Cancer Res       Date:  2021-06-09       Impact factor: 13.801

Review 7.  Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

Authors:  Finn Edler von Eyben; Giandomenico Roviello; Timo Kiljunen; Christian Uprimny; Irene Virgolini; Kalevi Kairemo; Timo Joensuu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-16       Impact factor: 9.236
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.